23:13 , Jan 25, 2018 |  BC Innovations  |  Strategy

Takeda rides Denali’s ATV

In its deal with Denali, Takeda has not only boosted its CNS pipeline, but also gained access to a delivery technology that could open the door to a host of CNS targets only druggable with...
00:45 , Jun 24, 2017 |  BioCentury  |  Strategy

Takeda’s modality operandi

Takeda Pharmaceutical Co. Ltd. is moving beyond its traditional small molecule approach into new modalities with the goal of delivering therapeutics that provide a step change for patients. To get there, Takeda is using a...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Company News

Affilogic, Takeda deal

Takeda and Affilogic partnered to validate and optimize therapies from Affilogic’s Nanofitins platform to treat CNS disorders. Affilogic will receive an undisclosed upfront payment and research funding and is eligible for development and sales milestones,...
07:00 , May 16, 2016 |  BC Week In Review  |  Company News

Bind Therapeutics, Affilogic deal

Bind will investigate the use of Affilogic’s Nanofitins targeting immuno-oncology checkpoints as ligand components of Accurins. Bind’s Accurins are polymeric nanoparticle-encapsulated therapeutics engineered to target specific cells and tissues at the site of disease. The...